Genelux (GNLX) Cash & Equivalents (2022 - 2026)

Genelux's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 32.8% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 32.8% decrease from a year earlier, with the FY2025 full-year figure at $12.2 million, up 42.62% from the prior year.
• Cash & Equivalents fell to $9.3 million in Q1 2026 per GNLX's latest filing, from $12.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $40.4 million in Q2 2024 and bottomed at $397000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $13.0 million (2025), against an average of $17.3 million.
• Across the five-year window, Cash & Equivalents jumped 1895.97% in 2023 and sank 86.36% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $397000.0 in 2022, then soared by 1895.97% to $7.9 million in 2023, then increased by 8.09% to $8.6 million in 2024, then surged by 42.62% to $12.2 million in 2025, then declined by 24.09% to $9.3 million in 2026.
• Per Business Quant, the three latest GNLX Cash & Equivalents figures stand at $9.3 million (Q1 2026), $12.2 million (Q4 2025), and $4.7 million (Q3 2025).